摘要
报告白细胞介素Ⅱ（ＩＬ－２）和淋巴因子激活杀伤细胞治疗中晚期肝癌３１例，其中１５例（Ａ组）联合非典型性肝切除术，１６例（Ｂ组）联合经股动脉插管化疗。随访７至１４个月，Ａ组全部健在，无肿瘤复发及转移，治疗后细胞免疫水平明显改善；Ｂ组平均生存期＞５．８４个月，其中１０例肿瘤平均直径缩小２～６．２ｃｍ，细胞免疫水平有所改善。对免疫治疗以及联合手术、插管化疗的作用进行了讨论。
31 cases of advanced primary liver cancer were treated by using IL-2 and LAK cells in which 15 cases were combined with surgery (group A) and 16 cases were combined with chemotherapy (group B). 7～14 months follow-up showed: In group A there was no recurence and metastasis, and the cell-mediated immunity was obviously improved. In group B, the average life time was more than 5. 84months, the tumor average diameter dicreased in 10 cases, and the cell-mediated immunity was also improved. The role of immunotherapy combined with surgery or chemotherapy was discussed.
